On 1 April 2014 the United States Patent & Trademark Office granted a patent for the use of OPAL A to treat therapeutic and cosmetic conditions.
Our first U.S patent, granted on 10 July 2012, claims the method of manufacture of OPAL A and the OPAL A composition defined by the process claims.
A continuation application is under examination.
A detailed summary of our current global patent status is available at the first ‘slider’ presentation on the Home page. This summary provides a better understanding of the significant success that Phoenix Eagle has achieved in protecting its valuable asset, OPAL A, the commercial value of which is evidenced by the increasing public awareness of and growth in demand for our Australian licensee’s OptiDerma products.